The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10659 malaria professionals are enjoying the free benefits of MalariaWorld today

ACTs

A protocol for systematic review and meta-analysis of optimizing treatment for malaria

September 12, 2020 - 14:56 -- Open Access
Author(s): 
Zhang R, Dong X, Wang J, Guo Y, Dai Y
Reference: 
Medicine (Baltimore). 2020 Sep 4;99(36):e22044

Malaria remains a global health threat for centuries. In recent years, a rising resistance of Plasmodium falciparum to current standard artemisinin-based combination therapies (ACTs) leads to increasing treatment failures and requires for optimized treatment. Here, we intend to make a systematic review and meta-analysis of optimizing treatment for malaria, so as to find a potential optimal treatment.

NOT Open Access | Prevalence of Plasmodium falciparum Kelch 13 (PfK13) and ubiquitin-specific protease 1 (pfubp1) gene polymorphisms in returning travellers from Africa reported in Eastern China

August 26, 2020 - 14:53 -- NOT Open Access
Author(s): 
Yan H, Kong X, Zhang T, Xiao H, Feng X, Tu H, Feng J
Reference: 
Antimicrob Agents Chemother. 2020 Aug 24:AAC.00981-20

Delayed clearance of Plasmodium falciparum by artemisinin-based combination therapies (ACTs) has already been observed in African isolates. Here, we aimed to investigate the prevalence of polymorphisms in two genes correlated with delayed parasite clearance, P. falciparum Kelch 13 (PfK13) and ubiquitin-specific protease 1 (pfubp1), among returning travellers from African countries reported in eastern China and to provide baseline data for antimalarial drug resistance (ART) surveillance and evaluation.

The lack of K13-propeller mutations associated with artemisinin resistance in Plasmodium falciparum in Democratic Republic of Congo (DRC)

August 25, 2020 - 07:55 -- Open Access
Author(s): 
Yobi DM, Kayiba NK, Mvumbi DM, Boreux R, Bontems S, Kabututu PZ, De Mol P, Speybroeck N, Mvumbi GL, Hayette MP
Reference: 
PLoS One. 2020 Aug 21;15(8):e0237791

Artemisinin-based combination therapies (ACTs) have been recommended by the World Health Organization (WHO) as first-line treatment of uncomplicated Plasmodium falciparum (P. falciparum) malaria since 2005 in Democratic Republic of Congo (DRC) and a regular surveillance of the ACT efficacy is required to ensure the treatment effectiveness. Mutations in the propeller domain of the pfk13 gene were identified as molecular markers of artemisinin resistance (ART-R).

Knowing the enemy: genetics to track antimalarial resistance

July 20, 2020 - 15:51 -- Open Access
Author(s): 
Ménard D, Mayor A
Reference: 
Lancet Infect Dis. 2020 Jul 14:S1473-3099(20)30271-1

In the absence of an effective vaccine, the efficacy of antimalarial chemotherapies  underpins the success of malaria control programmes. Artemisinin-based combination therapies (ACTs), which combine fast-acting artemisinin derivatives and longer-acting  partner drugs, are the mainstay of treatment of uncomplicated falciparum malaria in endemic regions.

Advances and Roadblocks in the Treatment of Malaria

July 14, 2020 - 15:45 -- Open Access
Author(s): 
Hanboonkunupakarn B, White NJ
Reference: 
Br J Clin Pharmacol. 2020 Jul 12

The deployment of artesunate for severe malaria and the artemisinin combination therapies (ACTs) for uncomplicated malaria has been a major advance in antimalarial therapeutics. These drugs have reduced treated mortality, accelerated recovery, and reduced treatment failure rates and transmission from the treated infection. Artemisinin derivatives remain highly effective against falciparum malaria in most malaria endemic areas but significant resistance has emerged in the Greater Mekong subregion of Southeast Asia.

NOT Open Access | Identification of compounds active against quiescent artemisinin-resistant Plasmodium falciparum parasites via the quiescent-stage survival assay (QSA)

July 14, 2020 - 15:42 -- NOT Open Access
Author(s): 
Reyser T, Paloque L, Ouji M, Nguyen M, Ménard S, Witkowski B, Augereau JM, Benoit-Vical F
Reference: 
J Antimicrob Chemother. 2020 Jul 12:dkaa250

Quiescence is an unconventional mechanism of Plasmodium survival, mediating artemisinin resistance. This phenomenon increases the risk of clinical failures following artemisinin-based combination therapies (ACTs) by slowing parasite clearance and allowing the selection of parasites resistant to partner drugs.

Subscribe to RSS - ACTs